These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 9798984

  • 1. Effect of phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN, Lee SC, Jackson KW, Tae WC, Schwartzott DG, McKee PA.
    Thromb Haemost; 1998 Oct; 80(4):637-44. PubMed ID: 9798984
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN, Jackson KW, McKee PA.
    Thromb Res; 2002 Feb 01; 105(3):263-70. PubMed ID: 11927133
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN, Kizim AI.
    Vopr Med Khim; 1984 Feb 01; 30(5):13-22. PubMed ID: 6084892
    [Abstract] [Full Text] [Related]

  • 11. Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin.
    Samama M, Castel M, Matsuo O, Hoylaerts M, Lijnen HR.
    Thromb Haemost; 1982 Feb 26; 47(1):36-40. PubMed ID: 7041325
    [Abstract] [Full Text] [Related]

  • 12. Increased urokinase and consumption of α2 -antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay.
    Longstaff C, Locke M.
    J Thromb Haemost; 2019 Jan 26; 17(1):195-205. PubMed ID: 30451372
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY, Fredenburgh JC, Stewart RJ, Rischke JA, Weitz JI.
    Thromb Haemost; 2001 Mar 26; 85(3):502-8. PubMed ID: 11307822
    [Abstract] [Full Text] [Related]

  • 15. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
    Jansen JW, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman TA.
    Thromb Haemost; 1987 Apr 07; 57(2):171-5. PubMed ID: 2440124
    [Abstract] [Full Text] [Related]

  • 16. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis.
    Marta-Enguita J, Navarro-Oviedo M, Machado FJDM, Bermejo R, Aymerich N, Herrera M, Zandio B, Pagola J, Juega J, Marta-Moreno J, Rodriguez JA, Páramo JA, Roncal C, Muñoz R, Orbe J.
    J Thromb Haemost; 2024 Apr 07; 22(4):1080-1093. PubMed ID: 38160727
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis.
    Sheffield WP, Eltringham-Smith LJ, Gataiance S, Bhakta V.
    BMC Biotechnol; 2009 Mar 03; 9():15. PubMed ID: 19257897
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.